Accelerated Ventures invests £3.5m in Biosignatures

The VC firm has now invested more than £25m in health and wellbeing startups, according to its website.

The fresh capital will be used to analyse thousands of blood samples with the goal of developing 20 new diagnostic screening tests. The tests will be targeting cancer and dementia detection.

Company
Biosignatures was founded in 2007 and is headquartered in Newcastle Upon Tyne. It has developed a machine-learning system that discovers new blood tests. Its first product is a prostate cancer test, which performed four times better than current clinical practice in a blind validation trial. The company employed 12 people in 2018.

People
Biosignatures – Dave Bramwell (chief technology officer).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Expansion
• UK / Ireland
• Healthcare
• Venture
• United Kingdom